Introduction
Introduction
High-grade non-muscle invasive bladder cancer (HG-NMIBC) is a clinically important subtype of bladder transitional cell carcinoma (TCC), accounting for 10-15% of all TCC at presentation [1] .The unpredictable nature of HG-NMIBC with regard to recurrence and progression to invasive or metastatic disease, presents many challenges for successful management. With no robust methods for predicting outcomes (recurrence, progression, Bacillus:Calmette-Guerin (BCG) failure) at initial diagnosis, patients may be under-treated with intravesical therapy alone or over-treated with immediate cystectomy, both with attributed adverse patient outcomes [2, 3] .
Multiple studies have described the importance of epigenetic modifications in tumourigenesis, most frequently apparent as inappropriate DNA methylation within gene promoterassociated CpG islands, and/or changes that lead to histone tail modification(s) [4, 5] .These modifications impact upon gene expression and promote tumourigenesis predominantly by silencing of tumour-suppressor and/or apoptotic pathway genes [5, 6] . Such epigeneticallymediated gene silencing has been demonstrated in NMIBC and muscle-invasive bladder cancer (MIBC), and is reported to be associated with tumour recurrence, progression, invasion, and metastasis, but also early events in tumour development such as the 'field-defect' phenomenon [7, 8] . Recent studies highlight the potential clinical utility of epigenetic biomarkers in bladder cancer, describing tumour, blood and urine DNA methylation markers of, for example, NMIBC recurrence or chemo-resistance in MIBC [9] [10] [11] .
Promoter-associated CpG Island methylation of the HOXA9, ISL1, NKX6-2, SPAG6, ZIC1 and ZNF154 genes are frequent findings in bladder cancer. In these cases, methylation appears associated with aggressive tumour characteristics, and may independently predict disease recurrence, progression, or disease-specific mortality (DSM) [9, 12, 13] . However the majority of these reports examine heterogeneous cohorts, comprising predominantly low/intermediategrade NMIBC; high-grade NMIBC has not been considered discretely for disease and/or subtype specific epigenetic modifications.
We assessed a unique cohort of patients with HG-NMIBC for inappropriate promoter-associated CpG Island methylation at initial presentation and removal of the primary tumour(s), 
Materials and Methods

Human tissue samples
The 
DNA extraction and bisulphite modification
Genomic DNA was extracted from tumour and control tissues using a standard phenol-chloroform extraction procedure [16] and subsequently bisulphite-modified as previously described [4] . Bisulphite conversion of DNA was confirmed in all cases by successful PCR using primers specific to bisulphite-converted DNA (primer sequences provided in supporting information S1 Table) . To increase the relative amount and stability of bisulphite-converted DNA, whole- genome amplification (WGA) was performed as previously described [4] (described further in supporting information S1 Text).
Pyrosequencing of bisulphite-converted DNA
CpG island sequences were identified from the UCSC Genome Browser (http://genome.ucsc. edu/), and imported into PyroMark Assay Design 2.0 Software for primer design (Qiagen, Manchester, UK). Dependent on the frequency and density of CpG dinucleotides within the sequence of interest, designed primers encompassed 4-7 consecutive CpGs in each gene (primer sequences in S1 Table and details of genomic location in S2 Table) . After PCR amplification of the target sequence, Pyrosequencing was performed using a PyroMark Q24 Pyrosequencer using PyroMark Q24 Software 2.0 and PyroMark Gold Q24 Reagents (Qiagen), as previously described [17] (S1 Text).
Methylation was stringently defined in tumours as comprising a mean level of methylation across the CpGs surveyed of greater than four standard deviations (4SD) above the mean in normal controls [4] . The number of tumours methylated (by this definition) for any given gene describes the frequency of methylation, whereas the mean percentage methylation of all CpGs surveyed describes the mean level of methylation for a tumour in any particular gene.
Quantitative RT-PCR
Total RNA was extracted from control and tumour samples using a standard guanidinium thiocyanate-phenol-chloroform protocol [16] , and complementary DNA synthesised as described previously [18] .Thermal cycling using SYBR (III) Green was as previously described [19] , with target genes normalised to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (S1 Table) as endogenous control (S1 Text). Relative quantification of transcript expression was performed using the 2 -ΔΔ cycle threshold (CT) method [20] . Reduced transcript expression in each tumour was regarded significant if lower than a 3-fold reduction relative to mean expression in control samples; the converse was true for increased transcript expression [18] (S1 Text).
Informatics and statistics
Microsoft Excel 2010 and STATA (v8, Stata Corporation, TX) were used to perform Fisher's exact, Students' t, and log-rank analyses, and sensitivity, specificity, and positive and negative predictive values of methylation with respect to clinical outcomes.
Results
Frequency of methylation within low/intermediate-and high-grade NMIBC
We initially determined the methylation status of the six candidate genes in the high-and low/ intermediate-grade tumour cohorts by Pyrosequence analyses of bisulphite-converted DNA. Inappropriate methylation of promoter-associated CpG islands (S2 Table) was a frequent finding in both cohorts for the NKX6-2, SPAG6, ZIC1 and ZNF154 genes, relative to normal bladder ( Table 2) . Table 2 shows that the methylation frequency in low/intermediate-grade tumours was lower for ISL1 than for all other genes investigated (2/12 tumours; 16.7%), although by comparison, methylation frequency increased within HG tumours (17/36; 45.0%, p = 0.091). Conversely, frequency of methylation was lower in HG-NMIBCs for HOXA9 (20/36; 55.6%) compared to low/intermediate-grade tumours (10/12; 83.3%, p = 0.167); (data summarised in Table 2 ).
To further investigate potential reasons for the observed differences in the frequency of methylation between the high-and low/intermediate-grade tumour cohorts for specific genes, we determined gene-specific methylation frequencies relative to the clinical characteristics of the HG tumours, encompassing one-year clinical outcomes of no-recurrence, recurrence, and progression.
For NKX6-2, SPAG6, ZIC1 and ZNF154, methylation frequencies in recurrence and progression tumours were marginally greater than their no-recurrence counterparts, and were overall broadly similar to the frequencies apparent in low/intermediate-grade tumours (Fig 1) .
HOXA9 demonstrated a similarly increased methylation frequency in recurrence and progression tumours relative to their no-recurrence counterparts, however, as shown in Fig 1, the methylation frequency in no-recurrence tumours was significantly lower compared to that observed in low/intermediate-grade tumours (p = 0.036). Although the trend of an increase in methylation frequency in recurrence and progression (relative to no-recurrence) tumours was (Fig 1) .
Mean methylation levels within low/intermediate-and high-grade NMIBC
Our methylation analyses also showed considerable differences in, and between, the mean and range of methylation levels within individual tumours (Fig 2) . Therefore, in addition to the analyses described above, we also assessed mean methylation levels within HG and low/intermediate-grade cohorts and within the HG tumour sub-types, to determine whether the level of methylation demonstrated any relationship with clinical characteristics. The mean level of methylation was greater, albeit not significantly, in HG relative to their low/intermediate-grade counterparts for the ISL1, SPAG6, NKX6-2, and ZNF154 genes ( Table 2 ). This increase approached significance for ISL1 (22.1% vs 36.5%, p = 0.061). Paradoxically, the mean level of methylation for HOXA9 was lower in HG compared to their low/intermediate-grade counterparts, again approaching significance (29.3%vs 44.0%, p = 0.057) ( Table 2) . Using this approach, we also determined gene-specific methylation levels within HG tumours and relative to their clinical outcomes. Mean methylation levels within ISL1 and HOXA9 were significantly higher in recurrence and progression tumours compared to their no-recurrence counterparts (43.3% vs. 20.9%, p = 0.016 and 34.5% vs. 17.6%, p = 0.017, respectively) (Fig 2) . The mean methylation level increase from no-recurrence to recurrence and progression tumours was not significant for NKX6-2, SPAG6, ZIC1 and ZNF154.
Correlation of methylation within clinical outcomes of high-grade NMIBC
We next determined the correlation between gene-specific methylation with clinical outcomes within the HG tumour cohort; HOXA9 and ISL1 were assessed as the only genes demonstrating a significant difference in frequency or level of methylation. HOXA9 promoter methylation demonstrated 72.7% specificity and an 84.2% positive predictive value (PPV) for tumour recurrence and/or progression within one year of initial diagnosis, whilst methylation within the ISL1 promoter demonstrated specificity of 81.8% and PPV 87.5% for the same clinical outcomes, shown in Table 3 . Moreover, concomitant methylation of HOXA9 and ISL1 at initial diagnosis predicted one-year recurrence and/or progression, with a PPV of 91.7%, whilst maintaining a specificity of 90.9%. To more rigorously assess association between these potential biomarkers and disease outcome, we employed logistical regression analysis. Table 3 shows that when considered individually, methylation of either HOXA9 or ISL1 attained statistical significance with tumour recurrence and/or progression (p = 0.050 and p = 0.047 respectively). However, in combination, while the biomarkers were less significantly associated with disease outcome (p = 0.067), they demonstrated a stronger odds ratio of tumour recurrence and/or progression than when either was considered separately (7.86 vs 4.74 and 5.73, respectively).
In addition to tumour behaviour we also considered promoter methylation as a predictor of disease-specific mortality: In this case, HOXA9 promoter methylation demonstrated 57.1% specificity and a 70.6% negative predictive value (NPV) for disease-specific mortality, whilst ISL1 methylation suggested 57.1% and 60.0% for these outcome measures.
Methylation-associated changes in gene expression in high-grade NMIBC
Quantitative RT-PCR was used to evaluate associations between methylation and gene expression in four of the six genes within a sub-set of 10-14 tumours, in comparison to controls. 56.3% (9 of 16) unmethylated tumours displayed expression levels similar to, or in some cases higher than, that apparent in controls.
Discussion
The epigenomic landscape of bladder cancer is an area of growing research interest [21] , specifically in relation to identifying clinically viable biomarkers. Due to the current limitations in predicting the diverse clinical outcomes observed in HG-NMIBC, and the present BCG shortage, biomarkers that guide clinical decisions are of particular importance [22, 23] . As described above, our analyses revealed frequent, and in some cases differential methylation, present at initial HG-NMIBC diagnosis, that appeared to correlate with tumour characteristics and clinical parameters. The six genes selected for analyses are predominantly members of transcription factor families, primarily regulating gene-expression, enzyme-binding, and cell differentiation [24] . Their selection for analyses was on the basis of their frequent inappropriate methylation in bladder cancer [9, 12, 13, 25] . In previous reports, HOXA9 and ZNF154 methylation has been associated with tumour recurrence, and ISL1 methylation with tumour progression in predominantly low/intermediate-grade tumours [9, 13] .
Our initial analyses revealed similar methylation frequencies in low/intermediate-and HG-NMIBC for NKX6-2, SPAG6, ZIC1 and ZNF154. In these cases, methylation frequencies were similar to those previously reported in the literature [9, 12, 13, 25] . However, a difference in the frequency of methylation was apparent between the low/intermediate-and HG-NMIBC cohorts for HOXA9 and ISL1 genes: although the methylation frequency of the HOXA9 promoter in low/intermediate-grade tumours was similar to that previously described in the literature [12, 13] , it was found at markedly lower frequency in HG-NMIBC. Conversely, for ISL1, methylation frequency in low/intermediate-grade tumours was lower than described previously by others [13] ; however, the methylation frequency increase that is apparent in the recurrence and progression tumours is more consistent with these reports. The differential methylation frequency in HOXA9 and ISL1 may relate to several confounders, including the method in this study employed to define tumour methylation, and the relatively few low/intermediate-grade tumours for analyses. However, the concordance between our methylation data and those reported by others for NKX6-2, SPAG6, ZIC1 and ZNF154, confirms the robustness of our approach. On this basis, we reasoned that the differences in methylation frequency observed for HOXA9 and ISL1 may be consequent to different clinical characteristics and/or outcomes within our HG tumour cohort; a phenomenon similarly described in, for example, breast, colon and pituitary tumours [4, 26, 27] . We therefore performed HG-NMIBC sub-type analyses and found that the methylation profiles of recurrence and progression tumours, although similar to each other, were mostly quite distinct from their no-recurrence counterparts; on this basis we grouped recurrence and progression tumours for analyses.
The methylation frequency in recurrence and progression tumours was consistently higher across all six genes compared to their no-recurrence counterparts; these differences were most pronounced for HOXA9 and ISL1 and achieved statistical significance for ISL1. Paradoxically, in HOXA9, no-recurrence, recurrence and progression tumours were less frequently methylated than in their low/intermediate-grade tumour counterparts. Although the reasons for this are unclear, possible explanations may relate to the number, or heterogeneity, of tumours investigated, though we cannot discount the possibility that there are epigenetic differences in particular genes between low/intermediate-and high-grade tumours. Conversely, methylation frequency in recurrence and progression tumours in ISL1 was markedly greater than in their low/intermediate-grade counterparts. Similar explanations to those described for HOXA9 might account for these observations.
Through quantitative Pyrosequence analyses, we determined mean methylation across multiple CpG sites showing that, further to methylation frequency differences, there exist differences in methylation levels between tumour cohorts for particular genes. Specifically, differences in mean methylation levels between low/intermediate-and HG tumours, and also between the no-recurrence, and their recurrence and progression tumour counterparts, analogous to observations reported by others in breast and colon cancer sub-types [26, 27] . For both HOXA9 and ISL1, there was a significant increase in the mean level of methylation in the recurrence and progression tumours compared to their no-recurrence counterparts.
The observed differences in methylation frequency and mean methylation level between these clinically divergent subgroups, suggests that the frequency and/or mean level of methylation increases with tumour aggressiveness. Similar trends have been reported in other tumour types [26, 27] and this is thought to represent accumulation of epigenetic aberrations over time, similar to the accumulation of genetic mutations and genomic instability apparent during tumour progression [28] .
Since our findings support previous associations of HOXA9 and ISL1 methylation with tumour characteristics and behaviour [9, 13] , we appraised potential clinical correlates of HOXA9 and ISL1 methylation, including their prognostic potential. In our HG-NMIBC cohort, HOXA9 or ISL1 methylation at initial diagnosis reliably predicted tumour recurrence or progression within one year. In this context, concurrent methylation of both HOXA9 and ISL1 improved the positive predictive value to 91.7%, comparing favourably with other postulated biomarkers of recurrent/progressive disease in NMIBC [13, 29] . Moreover, logistic regression appeared to confirm that these findings were not consequent to methylation in a single gene. Furthermore, and as previously described [9, 13] , concurrent methylation in HOXA9 and ISL1 was associated with DSM and reduced overall survival, however, this did not reach statistical significance. In this context, we recognise that the number of tumours available for investigation and in the absence of similar reports, that the associations we report between inappropriate methylation and HG-NMIBC disease outcome will require validation in larger, independent tumour cohorts.
Finally, to reveal potential functional relevance of methylation within high-grade disease, we assessed the relationship between methylation and gene expression; across the four genes studied, we found an association of abnormal methylation with reduced transcript expression, consistent with findings from other groups [9, 13] . These findings were not significant, possibly relating to number of tumours studied, or the passenger/driver phenomenon, whereby epigenetic marks may be present but not causative of altered gene expression [30] .
These findings are the first to report similarities and differences of gene-associated methylation in HG-NMIBC relative to low/intermediate-grade tumours. Furthermore, we have shown that specific methylation patterns at initial diagnosis predict one-year HG-NMIBC clinical outcomes, pointing to the exciting potential for methylation as a prognostic biomarker in this clinically unpredictable disease. Further investigations exploiting genome-wide array analyses are required to further characterise epigenetic similarities and differences between low/intermediate-and HG-NMIBC, and to reveal biomarkers that may serve as therapeutic targets or guide clinical management, such as the timing, dose and length of BCG therapy, or timing of cystectomy.
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